Can Home Tech Finally Fix Hospital Readmissions?

The READI-Home challenge invites innovators to build home-use devices that prevent hospital readmissions, with FDA sprint access by December 2026

3 Jun 2026

America's Food and Drug Administration has launched a competition to fast-track home-use medical devices aimed at reducing hospital readmissions, one of US healthcare's most persistent and expensive structural problems.

Called the READI-Home Innovation Challenge, the programme opened on April 7, 2026 under the agency's Center for Devices and Radiological Health. Developers have until September 30 to submit proposals, which must include a device description, feasibility evidence, and a Data Development Plan covering clinical and non-clinical testing, all within 16 pages.

Readmission costs are measurable and steep. Among patients with chronic conditions, 30-day readmission rates reach 18.4%, with more than half of those returns triggered by complications unrelated to the original diagnosis. Each readmission consistently costs roughly 12% above the initial hospital stay, a burden that improved home monitoring could reduce.

Acceptance among patients is not in question. A 2024 JAMA study found that nearly half of US adults consider hospital-at-home care acceptable.

Up to nine technologies will advance into a collaboration phase beginning December 5, 2026, where developers receive intensive sessions with FDA scientists and access to agency research facilities. Selected devices may also qualify for Breakthrough Device designation, a pathway that substantially shortens the route to market.

For companies working in remote monitoring, AI-enabled home diagnostics, or caregiver-operated recovery tools, READI-Home offers early regulatory alignment before clinical trials begin. That positioning carries practical weight in a sector where late-stage regulatory friction is common.

The challenge builds on CDRH's existing Home as a Health Care Hub initiative. As hospital-at-home programmes expand across US health systems, federal support has shifted from concept to active development incentive. Whether that incentive translates into deployable devices at scale remains to be seen.